Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold

Shares of Novavax (NVAX) lost nearly 20% on Wednesday after the company announced that the FDA has placed a clinical hold on its experimental COVID-19-Influenza Combination ("CIC") and stand-alone influenza vaccine candidates. This clinical hold was placed in response to a 'spontaneous report' of motor neuropathy in a study participant who took the CIC vaccine as part of a phase II study conducted outside the United States last year in January. While this study was completed in July 2023, the adverse event ...